摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(benzylthio)-5-(pyridin-4-yl)-1,3,4-oxadiazole | 105491-55-2

中文名称
——
中文别名
——
英文名称
2-(benzylthio)-5-(pyridin-4-yl)-1,3,4-oxadiazole
英文别名
2-benzylthiothio-5-(4-pyridyl)-1,3,4-oxadiazole;Pyridine, 4-[5-[(phenylmethyl)thio]-1,3,4-oxadiazol-2-yl]-;2-benzylsulfanyl-5-pyridin-4-yl-1,3,4-oxadiazole
2-(benzylthio)-5-(pyridin-4-yl)-1,3,4-oxadiazole化学式
CAS
105491-55-2
化学式
C14H11N3OS
mdl
MFCD01932711
分子量
269.327
InChiKey
JYGQRLOMJKRAQM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    19
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.07
  • 拓扑面积:
    77.1
  • 氢给体数:
    0
  • 氢受体数:
    5

SDS

SDS:1e279681d2afbc40e29b49817147ed1a
查看

反应信息

  • 作为反应物:
    描述:
    2-(benzylthio)-5-(pyridin-4-yl)-1,3,4-oxadiazole间氯过氧苯甲酸 作用下, 以 二氯甲烷 为溶剂, 生成 4-(5-Phenylmethanesulfinyl-[1,3,4]oxadiazol-2-yl)-pyridine
    参考文献:
    名称:
    Novel inhibitors of cell adhesion molecule expression
    摘要:
    2-Alkylsulfinyl-1,3,4-oxadiazoles have been identified as novel inhibitors of cell adhesion molecule expression on endothelial cells. These compounds have been shown to inhibit the up-regulation of ELAM-1 and VCAM-1 on activated human umbilical vein endothelial cells (HUVECs) as measured by ELISA. Copyright (C) 1996 Elsevier Science Ltd
    DOI:
    10.1016/s0960-894x(96)00504-5
  • 作为产物:
    描述:
    异烟酸甲酯一水合肼三乙胺 、 sodium hydroxide 作用下, 以 乙醇N,N-二甲基甲酰胺 为溶剂, 反应 5.0h, 生成 2-(benzylthio)-5-(pyridin-4-yl)-1,3,4-oxadiazole
    参考文献:
    名称:
    Identification of Glycogen Synthase Kinase-3 Inhibitors with a Selective Sting for Glycogen Synthase Kinase-3α
    摘要:
    The glycogen synthase kinase-3 (GSK-3) has been linked to the pathogenesis of colorectal cancer, diabetes, cardiovascular disease, acute myeloid leukemia (AML), and Alzheimer's disease (AD). The debate on the respective contributions of GSK-3 alpha and GSK-3 beta to AD pathology and AML is ongoing. Thus, the identification of potent GSK-3 alpha-selective inhibitors, endowed with favorable pharmacokinetic properties, may elucidate the effect of GSK-3 alpha inhibition in AD and AML models. The analysis of all available crystallized GSK-3 structures provided a simplified scheme of the relevant hot spots responsible for ligand binding and potency. This resulted in the identification of novel scorpion shaped GSK-3 inhibitors. It is noteworthy, compounds 14d and 15b showed the highest GSK-3 alpha selectivity reported so far. In addition, compound 14d did not display significant inhibition of 48 out of 50 kinases in the test panel. The GSK-3 inhibitors were further profiled for efficacy and toxicity in the wild-type (wt) zebrafish embryo assay.
    DOI:
    10.1021/jm300309a
点击查看最新优质反应信息

文献信息

  • SMALL MOLECULE INHIBITORS OF SUPEROXIDE DISMUTASE EXPRESSION
    申请人:Northwestern University
    公开号:US20160214969A1
    公开(公告)日:2016-07-28
    Disclosed are new small molecules and the uses thereof for inhibiting superoxide dismutase (SOD) expression. Also disclosed are pharmaceutical compositions comprising the small molecule inhibitors which may be administered in methods of treating diseases or disorders associated with elevated SOD expression or activity, including neurological diseases and disorders such as amyotrophic lateral sclerosis (ALS).
    公开了新的小分子及其用途,用于抑制超氧化物歧化酶(SOD)的表达。还公开了包含所述小分子抑制剂的药物组合物,该药物组合物可以通过用于治疗与SOD表达或活性升高相关的疾病或失调的方法来给药,包括神经疾病和失调,如肌萎缩侧索硬化症(ALS)。
  • GSK-3BETAINHIBITOR
    申请人:Itoh Fumio
    公开号:US20100069381A1
    公开(公告)日:2010-03-18
    For the purpose of providing a GSK-3β inhibitor containing an oxadiazole compound or a salt thereof or a prodrug thereof useful as an agent for the prophylaxis or treatment of a GSK-3β-related pathology or disease, the present invention provides a GSK-3β inhibitor containing a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.
    为了提供一种含有噁二唑化合物或其盐或其前药的GSK-3β抑制剂,用作GSK-3β相关病理或疾病的预防或治疗剂,本发明提供了一种含有由以下式(I)表示的化合物的GSK-3β抑制剂: 其中每个符号如规范中定义,或其盐或其前药。
  • Synthesis, molecular modeling and biological evaluation of 2-(benzylthio)-5-aryloxadiazole derivatives as anti-tumor agents
    作者:Kai Liu、Xiang Lu、Hong-Jia Zhang、Juan Sun、Hai-Liang Zhu
    DOI:10.1016/j.ejmech.2011.11.015
    日期:2012.1
    A series of 2-(benzylthio)-5-aryloxadiazole derivatives have been designed and synthesized, and their biological activities are also evaluated for EGFR inhibitory activity. Fourteen compounds among the twenty compounds are reported for the first time. Their chemical structures are characterized by 1H NMR, MS, and elemental analysis. Anti-proliferative and EGFR inhibition assay results have demonstrated
    已经设计和合成了一系列2-(苄硫基)-5-芳基恶二唑衍生物,并且还评估了它们的生物活性对EGFR的抑制活性。首次报道了二十种化合物中的十四种化合物。它们的化学结构通过1 H NMR,MS和元素分析进行表征。抗增殖和EGFR抑制测定的结果已经证实,化合物3e中示出了最有效的生物活性(IC 50  = 1.09μM为MCF-7和IC 50  = 1.51μM为EGFR)。已执行对接仿真以定位化合物3e进入EGFR活性位点以确定可能的结合模型,估计结合自由能值为-10.7 kcal / mol。在肿瘤生长抑制中具有有效抑制活性的化合物3e可能是有前途的抗肿瘤主导化合物,值得进一步研究。
  • Synthesis and Bioactivities of Novel 1,3,4-oxadiazole Derivatives Containing Pyridine Moiety
    作者:Guo-Xiang Sun、Yan-Xia Shi、Zhao-Hui Sun、Ming-Yan Yang、Hong-Ke Wu、Jian-Quan Weng、Cheng-Xia Tan、Xing-Hai Liu、Bao-Ju Li、Yong-Gang Zhang
    DOI:10.2174/1570180811666140522002929
    日期:2014.8.31
    In this paper, some novel 1,3,4-oxadiazole derivatives containing 4-pyridyl group were synthesized under microwave assistant condition by multi-step reactions. The structures were characterized by 1H NMR, MS and elemental analyses. The target compounds were evaluated for their fungicidal activities, and the results indicated that some of the title compounds displayed good antifungal activities.
    本文通过多步反应在微波辅助条件下合成了一系列含有4-吡啶基的新型1,3,4-噁二唑衍生物,并利用1H NMR、MS和元素分析对其结构进行了表征。对目标化合物的杀菌活性进行了评估,结果表明,部分标题化合物展现出了良好的抗真菌活性。
  • COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS
    申请人:THE BROAD INSTITUTE, INC.
    公开号:US20160031870A1
    公开(公告)日:2016-02-04
    Disclosed are compounds that can be used for treating tuberculosis.
    本发明涉及用于治疗结核病的化合物。
查看更多